Journey towards universal viral load monitoring in Maputo, Mozambique: many gaps, but encouraging signs

Int Health. 2017 Jul 1;9(4):206-214. doi: 10.1093/inthealth/ihx021.

Abstract

Introduction: Viral load (VL) monitoring for people on antiretroviral therapy (ART) is extremely challenging in resource-limited settings. We assessed the VL testing scale-up in six Médecins Sans Frontières supported health centres in Maputo, Mozambique, during 2014-15.

Methods: In a retrospective cohort study, routine programme data were used to describe VL testing uptake and results, and multi-variate logistical regression to estimate predictors of VL testing uptake and suppression.

Results: Uptake of a first VL test was 40% (17 236/43 579). Uptake of a follow-up VL test for patients with a high first VL result was 35% (1095/3100). Factors associated with a higher uptake included: age below 15 years, longer time on ART and attending tailored service delivery platforms. Virological suppression was higher in pregnant/breastfeeding women and in community ART Group members. Patients with a high first VL result (18%; 3100/17 236) were mostly younger, had been on ART longer or had tuberculosis. Out of 1095 attending for a follow-up VL test, 678 (62%) had virological failure. Of those, less than one-third had started second line ART.

Conclusion: This was the first study describing the uptake and results of VL testing scale-up in Mozambique. Identified gaps show patient and programmatic challenges. Where service delivery was customized to patient needs, VL monitoring was more successful.

Keywords: Antiretroviral therapy; HIV; Mozambique; Operational research; Sub-Saharan Africa; Viral load monitoring.

MeSH terms

  • Adolescent
  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Drug Monitoring / statistics & numerical data*
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Mozambique
  • Pregnancy
  • Program Evaluation
  • Retrospective Studies
  • Viral Load / drug effects
  • Viral Load / statistics & numerical data*
  • Young Adult

Substances

  • Anti-HIV Agents